NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $17.81 +0.48 (+2.77%) (As of 09:14 AM ET) Add Compare Share Share Today's Range$17.81▼$17.8150-Day Range$14.77▼$31.0052-Week Range$8.24▼$32.88Volume200 shsAverage Volume42,600 shsMarket Capitalization$212.65 millionP/E RatioN/ADividend YieldN/APrice Target$62.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Q32 Bio alerts: Email Address Q32 Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside259.2% Upside$62.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.74) to ($4.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector538th out of 896 stocksPharmaceutical Preparations Industry247th out of 424 stocks 3.6 Analyst's Opinion Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 4 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for QTTB. Previous Next 0.0 Dividend Strength Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTTB. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Q32 Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows2 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($10.74) to ($4.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Q32 Bio Stock (NASDAQ:QTTB)Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Read More QTTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTTB Stock News HeadlinesJuly 1, 2024 | prnewswire.comQ32 Bio Joins Russell 3000® IndexMay 22, 2024 | msn.comLeerink Partners Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationJuly 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 21, 2024 | markets.businessinsider.comBuy Rating Justified by Q32 Bio’s Promising Pipeline and Market PotentialMay 9, 2024 | investorplace.comQTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024May 9, 2024 | prnewswire.comQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comVeru, Theravance Biopharma, Adial Pharmaceuticals among healthcare moversApril 12, 2024 | investing.comQ32 Bio stock target upgraded on strong drug potentialJuly 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.April 8, 2024 | uk.investing.comQ32 Bio Inc (QTTB)April 5, 2024 | uk.investing.comQ32 Bio names Lee Kalowski as President and CFOApril 3, 2024 | finance.yahoo.comQ32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerSee More Headlines Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/04/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$62.25 High Stock Price Target$100.00 Low Stock Price Target$45.00 Potential Upside/Downside+259.2%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($32.5890) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-22,326.84% Return on Equity-117.63% Return on Assets-70.92% Debt Debt-to-Equity Ratio0.19 Current Ratio4.19 Quick Ratio4.19 Sales & Book Value Annual Sales$1.16 million Price / Sales178.38 Cash FlowN/A Price / Cash FlowN/A Book Value$22.47 per share Price / Book0.77Miscellaneous Outstanding Shares11,940,000Free Float10,019,000Market Cap$206.92 million OptionableN/A Beta-0.34 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 48)CEO & Director Comp: $852.63kDr. Shelia M. Violette Ph.D. (Age 63)Co-founder, Chief Scientific Officer & President of Research Comp: $619.93kDr. Jason A. Campagna M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $680.93kMr. Lee H. Kalowski M.B.A. (Age 43)CFO, President & Treasurer Dr. Saul Fink Ph.D.Chief Technology OfficerMr. David Appugliese J.D.Senior VP & Head of PeopleMs. Maria Marzilli M.P.H.Executive Vice President of Corporate Strategy & Program OperationsMs. Kathryn E. Golden M.B.A.Head of Chemistry, Manufacturing & ControlsMore ExecutivesKey CompetitorsABIVAX Société AnonymeNASDAQ:ABVXCogent BiosciencesNASDAQ:COGTAbCellera BiologicsNASDAQ:ABCLAurinia PharmaceuticalsNASDAQ:AUPHDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 22,335 shares on 5/17/2024Ownership: 0.685%ARCH Venture Management LLCBought 320,482 shares on 5/15/2024Ownership: 9.831%Affinity Asset Advisors LLCBought 27,777 shares on 5/15/2024Ownership: 0.852%Platinum Investment Management Ltd.Bought 109,964 shares on 5/14/2024Ownership: 3.373%Acadian Asset Management LLCBought 3,695 shares on 5/10/2024Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions QTTB Stock Analysis - Frequently Asked Questions Should I buy or sell Q32 Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Q32 Bio in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QTTB shares. View QTTB analyst ratings or view top-rated stocks. What is Q32 Bio's stock price target for 2024? 5 Wall Street research analysts have issued 12 month price targets for Q32 Bio's shares. Their QTTB share price targets range from $45.00 to $100.00. On average, they predict the company's share price to reach $62.25 in the next year. This suggests a possible upside of 259.2% from the stock's current price. View analysts price targets for QTTB or view top-rated stocks among Wall Street analysts. How have QTTB shares performed in 2024? Q32 Bio's stock was trading at $17.04 at the beginning of the year. Since then, QTTB stock has increased by 1.7% and is now trading at $17.33. View the best growth stocks for 2024 here. When is Q32 Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our QTTB earnings forecast. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) released its quarterly earnings data on Thursday, May, 9th. The company reported ($13.15) EPS for the quarter, missing analysts' consensus estimates of ($1.42) by $11.73. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QTTB) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
